The weight loss outcomes are not comparable
Phase 2 liver disease data published in Nature Medicine (2024) identifies retatrutide as the compound with the most comprehensive hepatic fat reduction profile currently under clinical investigation, making it the correct peptide for NAFLD and MASH preclinical study designs
At this appointment you will have a couple of steps to qualify for Semiglutide Weight Loss Plan (Plan to spend 45 minutes with us at this appointment)
For the phase III clinical program, a total of eight studies were initiated that investigated the efficacy and safety of tirzepatide in comparison to various other established antidiabetic medications in T2D either in monotherapy, combination with metformin as baseline therapy, or metformin and insulin glargine as a baseline
[DOI] [PMC free article] [PubMed] [Google Scholar] 11.Abdi M., Lamardi Z.H., Shirjan F., Mohammadi L., Abadi S.S.D., Massoudi N., Zangiabadian M., Nasiri M.J